Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care. Results from the STAR study

European Psychiatry

Volumn 23, Issue 5, 2008, Pages 336-343

  Taylor, David ^a,d   Hanssens, Linda ^b   Loze, Jean Yves ^c   Pans, Miranda ^b   L'Italien, Gilbert ^b   Marcus, Ronald N ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

^c Otsuka Pharmaceuticals France   (France)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Aripiprazole; Atypical antipsychotic; Naturalistic study; Patient preference; Quality of life; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG PREFERENCE; FEMALE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PATIENT ATTITUDE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CHOICE BEHAVIOR; COMMUNITY MENTAL HEALTH SERVICES; CONSUMER SATISFACTION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUALITY OF LIFE; QUESTIONNAIRES; QUINOLONES; SCHIZOPHRENIA;

EID: 47749087425     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2008.03.006     Document Type: Article

References (27)

1. Awad A.G., and Voruganti L.N. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18 (2004) 877-893
2. Corey-Lisle PK, Hardy SA, Impellizzeri CA. Aripiprazole vs haloperidol in acute mania: health-related quality of life (HRQoL). Abstract and poster presented at the 56th Institute on Psychiatric Services, Atlanta, GA, USA, October 6-10, 2004.
3. de Millas W., Lambert M., and Naber D. The impact of subjective well-being under neuroleptic treatment on compliance and remission. Dialogues Clin Neurosci 8 (2006) 131-136
4. Dolan P. Modelling valuations for EQ-5D health states. Medical Care 35 (1997) 1095-1108
5. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16 (1990) 199-208
6. Gilmer T.P., Dolder C.R., Lacro J.P., Folsom D.P., Lindamer L., Garcia P., et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 161 (2004) 692-699
7. Haro J.M., Edgell E.T., Novick D., Alonso J., Kennedy L., Jones P.B., et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 111 (2005) 220-231
8. Heinrichs D.W., Hanlon T.E., and Carpenter Jr. W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10 (1984) 388-398
9. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63 (2006) 1079-1087
10. Karow A., and Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl) 162 (2002) 3-10
11. Kerwin R., Millet B., Herman E., Banki C.M., Lublin H., Pans M., et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients: Schizophrenia Trial of Aripiprazole (STAR) study. Eur Psychiatry 22 7 (2007) 433-443
12. Konnopka A., Gunther O.H., Angermeyer M.C., and Konig H.H. Discriminative ability, construct validity and sensitivity to change of the EQ-5D quality of life questionnaire in paranoid schizophrenia. Psychiatr Prax 33 (2006) 330-336
13. Lambert M., and Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 18 Suppl 2 (2004) 5-17
14. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
15. Lindstrom E., and Bingefors K. Patient compliance with drug therapy in schizophrenia: economic and clinical issues. Pharmacoeconomics 18 (2000) 106-124
16. L'Italien G, Hanssens L, Marcus R, McQuade R, Carson W, Beuzen J-N. Metabolic effects of aripiprazole versus Standard of Care (The STAR Trial). American Psychiatric Association 159th Annual Meeting, Toronto, Canada, May 20-25, 2006.
17. Mitchell A.J. Adherence behaviour with psychotropic medication is a form of self-medication. Med Hypotheses 68 1 (2007) 12-21
18. Nasrallah H.A., and Lasser R. Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol 20 6 Suppl (2006) 57-61
19. NICE. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia (2002), United Kingdom: National Institute for Clinical Excellence, London
20. Prieto L., Novick D., Sacristan J.A., Edgell E.T., and Alonso J. A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatr Scand Suppl 107 416 (2003) 24-29
21. Prieto L., Sacristan J.A., Hormaechea J.A., Casado A., Badia X., and Gómez J.C. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin 20 (2004) 827-835
22. Roick C., Thierfelder K., Heider D., Klemm T., Paschke R., and Angermeyer M.C. Quality of life instruments and health state preferences to assess effects of medical interventions for mentally and medically ill patients. Psychiatr Prax 31 (2004) 128-137
23. Sebastian C.S., Glazer W., and Buckley P.F. Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia. Curr Med Chem 11 (2004) 329-342
24. Swartz M.S., Perkins D.O., Stroup T.S., Davis S.M., Capuano G., Rosenheck R.A., et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 164 3 (2007) 428-436
25. Tandon R., Marcus R.N., Stock E.G., Riera L.C., Kostic D., Pans M., et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 84 (2006) 77-89
26. Voruganti L., Cortese L., Owyeumi L., Kotteda V., Cernovsky Z., Zirul S., et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 57 (2002) 201-208
27. Wolf J., Janssen F., Lublin H., Salokangas R.K.R., Allain H., Smeraldi E., et al. A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). Curr Med Res Opin 23 (2007) 2313-2323